Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT3001 in Acute Ischemic Stroke
NCT07754825Phase 2Not yet recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of odatroltide in ischemic stroke, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
odatroltide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07754825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754825.